About ImmUniverse
Improved diagnostic and therapeutic options for patients living with ulcerative colitis and atopic dermatitis: this is the ultimate aim of the ImmUniverse project.
New insights into disease severity and progression will enable personalised therapy for each individual patient.
Duration
5 Years
Budget
31 Mio.
26 Partners
10 Countries
“ImmUniverse aims not only to identify disease-specific signatures, but also cross-disease signatures of the underlying pathological pathways between ulcerative colitis and atopic dermatitis using multiomic approaches. The validation of new disrupted liquid biopsies for the molecular characterization of the skin and colon will allow us to non-invasively monitor the response to treatment and disease progression in our patients.”
Prof. Stefania Vetrano, ImmUniverse Coordinator
Assistant Professor of Gastroenterology at Humanitas University in Milan
Background
Immune-mediated inflammatory diseases (IMIDs) result from abnormal activities of the body’s immune system. Ulcerative colitis and atopic dermatitis are part of this category of illnesses which are an increasing medical burden in industrialised countries worldwide. The enormous heterogeneity in disease outcome and response to targeted therapies makes it difficult to tailor the treatment of IMIDs to individual patients. This is where ImmUniverse aims at introducing ground-breaking new insights and practical improvements for patients.
The ImmUniverse Team
